IP Library Granted Patent US 8,187,601
Granted Patent B2
US 8,187,601 · App. 12/494,965 · Granted May 29, 2012

Fibroblast growth factor receptor 3 (FGFR3) binding proteins

Assignee: AVEO Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,187,601
App. No.
12/494,965
Granted
May 29, 2012
Kind
B2
Abstract

Monoclonal antibodies that bind and inhibit activation of fibroblast growth factor receptor 3 (FGFR3) are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of FGFR3.

Claims (38)

1. An isolated binding protein that binds human fibroblast growth factor receptor 3 (FGFR3) comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of:

(a) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 17 (15D8), a CDR Hb comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 18 (15D8), and a CDR H3 comprising the sequence SEQ ID NO: 19 (15D8); and

(ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 22 (15D8), a CDR L2 comprising the sequence SEQ ID NO: 23 (15D8), and a CDR L3 comprising the sequence SEQ ID NO: 24 (15D8);

(b) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 17 (27H2, 4E7(7D12)), a CDR H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 25 (27H2, 4E7(7D12)), and a CDR H3 comprising the sequence SEQ ID NO: 19 (27H2, 4E7(7D12)); and

(ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 22 (27H2, 4E7(7D12)), a CDR L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 26 (27H2, 4E7(7D12)), and a CDR L3 comprising the sequence SEQ ID NO: 27 (27H2, 4E7(7D12));

(c) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 17 (2G4), a CDR H2 comprising the sequence SEQ ID NO: 28 (2G4), and a CDR H3 comprising the sequence SEQ ID NO: 19 (2G4); and

(ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 22 (2G4), a CDR L2 comprising the sequence SEQ ID NO: 26 (2G4), and a CDR L3 comprising the sequence SEQ ID NO: 27 (2G4); and

(d) (i) an immunoglobulin heavy chain variable region comprising a CDR H1 comprising the sequence SEQ ID NO: 29 (20B4), a CDR H2 comprising the sequence SEQ ID NO: 18 (20B4), and a CDR H3 comprising the sequence SEQ ID NO: 30 (20B4); and

(ii) an immunoglobulin light chain variable region comprising a CDR L1 comprising the sequence SEQ ID NO: 31 (20B4), a CDR L2 comprising the sequence SEQ ID NO: 32 (20B4), and a CDR L3 comprising the sequence SEQ ID NO: 33 (20B4).

2. The binding protein of claim 1 , wherein the CDR sequences are interposed between human and humanized framework sequences.

3. The binding protein of claim 1 , wherein the binding protein is a monoclonal antibody or antigen binding protein fragment thereof.

4. An isolated binding protein that binds human fibroblast growth factor receptor 3 (FGFR3) comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region selected from the group consisting of:

(a) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 2 (15D8), and

an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 4 (15D8);

(b) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6 (27H2), and

an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 (27H2);

(c) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10 (2G4), and

an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 (2G4);

(d) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 12 (4E7(7D12)), and

an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 8 (4E7(7D12));

(e) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 14 (20B4), and

an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 16 (20B4); and

(f) an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 70 (Hu15D8), and

an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO: 72 (Hu15D8).

5. The binding protein of claim 4 , wherein the immunoglobulin heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 2 (15D8), and the immunoglobulin light chain variable region comprises the amino acid sequence of SEQ ID NO: 4 (15D8).

6. The binding protein of claim 4 , wherein the immunoglobulin heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 70 (Hu15D8), and the immunoglobulin light chain variable region comprises the amino acid sequence of SEQ ID NO: 72 (Hu15D8).

7. An isolated binding protein that binds human fibroblast growth factor receptor 3 (FGFR3) comprising an immunoglobulin heavy chain and an immunoglobulin light chain selected from the group consisting of:

(a) an immunoglobulin heavy chain of SEQ ID NO: 39 (15D8), and an immunoglobulin light chain of SEQ ID NO: 41 (15D8);

(b) an immunoglobulin heavy chain of SEQ ID NO: 43 (27H2), and an immunoglobulin light chain of SEQ ID NO: 45 (27H2);

(c) an immunoglobulin heavy chain of SEQ ID NO: 47 (2G4), and an immunoglobulin light chain of SEQ ID NO: 49 (2G4);

(d) an immunoglobulin heavy chain of SEQ ID NO: 51 (4E7(7D12)), and an immunoglobulin light chain of SEQ ID NO: 53 (4E7(7D12));

(e) an immunoglobulin heavy chain of SEQ ID NO: 55 (20B4), and an immunoglobulin light chain of SEQ ID NO: 57 (20B4);

(f) an immunoglobulin heavy chain of SEQ ID NO: 66 (Chimeric 15D8), and an immunoglobulin light chain of SEQ ID NO: 68 (Chimeric 15D8); and

(g) an immunoglobulin heavy chain of SEQ ID NO: 74 (Hu15D8), and an immunoglobulin light chain of SEQ ID NO: 76 (Hu15D8).

8. The binding protein of claim 7 , wherein the immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 39 (15D8), and the immunoglobulin light chain comprises the amino acid sequence of SEQ ID NO: 41 (15D8).

9. The binding protein of claim 7 , wherein the immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 66 (Chimeric 15D8), and the immunoglobulin light chain comprises the amino acid sequence of SEQ ID NO: 68 (Chimeric 15D8).

10. The binding protein of claim 7 , wherein the immunoglobulin heavy chain comprises the amino acid sequence of SEQ ID NO: 74 (Hu15D8), and the immunoglobulin light chain comprises the amino acid sequence of SEQ ID NO: 76 (Hu15D8).

11. The binding protein of claim 4 or 7 , wherein the binding protein is a monoclonal antibody or an antigen binding fragment thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2009
From: WENG, ZHIGANG; WINSTON, WILLIAM M., JR.; BREAULT, LYNE; MEETZE, KRISTAN; WEILER, SOLLY; GYURIS, JENO
To: AVEO PHARMACEUTICALS, INC.
Reel/Frame 023126/0515 →
Continuity (2)
Provisional Application 61077278 · Jul 1, 2008
Related Publication 20100003258A1 · Jan 7, 2010